Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner.

Scientists in Dundee help to create drug to fight Parkinson’s

Scientists at Dundee University are working to help cure Parkinson's
Scientists at Dundee University are working to help cure Parkinson's

Scientists at Dundee University have agreed a multi-million pound partnership with a drugs company to create a possible cure for Parkinson’s.

The university’s drug discovery unit (DDU) has joined forces with Korean-based Bukwang Pharmaceutical Company in an effort to develop a drug to combat the disease.

The neurological disorder, the second most common after Alzheimer’s, affects around two in every 1,000 people.

It is estimated there are around 6.1 million people worldwide and 120,000 in the UK living with the condition.

A key event in the onset of Parkinson’s is the increase of a small protein in the brain called alpha-synuclein which can kill nerve cells.

Research at Oxford University has shown that an enzyme, USP8, prevents the natural break down of alpha-synuclein.

Working with Dr George Tofaris, at Oxford University, the DDU has identified a series of drug-like molecules which block USP8 and so could be a cure for the disease.

Bukwang will run a three year programme of work at Dundee University  and Oxford University to work on a tablet to halt the creation of USP8.

Professor Paul Wyatt, head of the DDU, said: “We are delighted to be announcing this partnership with Bukwang Pharm.

“Drug discovery for neurological disorders is especially challenging and an area where academia and industry need to be working together.

“This project brings together the clinical and translational research expertise in Oxford with Dundee’s professional drug discovery capabilities allowing us to move one stage further towards a treatment.”

Hee-Won Yoo, chief executive officer of Bukwang Pharm, said the company was very impressed with the DDU’s depth of expertise and track record.

She said: “We have a firm focus on research and development and a real commitment to innovation in drug development.”

Dr Beckie Port, research manager at Parkinson’s UK, said: “It’s an exciting time for Parkinson’s research.

“Finding treatments that target the alpha-synuclein protein holds promise for one day slowing or stopping the progression of Parkinson’s – something no current treatment can do.

“Our increased understanding of the biology of the condition means we’re now at a stage to turn our wealth of knowledge into much-needed treatments for people with Parkinson’s.”

Already a subscriber? Sign in

[[title]]

[[text]]